I-Nicotinamide adenine dinucleotide (NAD+) yindawo ethandwa kakhulu zizazinzulu ekhaya nakwamanye amazwe. Uninzi lwezazinzulu zikholelwa ukuba inqanaba le-NAD+ linxulumene kakhulu nezifo ezingapheliyo ezinxulumene nobudala, ezifana nomhlaza, ukutyeba kakhulu, uxinzelelo lwegazi oluphezulu kunye nesifo seswekile.
I-Keratinocyte carcinoma (KC) yeyona tumor ixhaphakileyo kubantu abanesikhumba esimhlophe, kuquka i-basal cell carcinoma (BCC) kunye ne-squamous cell carcinoma (cSCC). Kutshanje, izazinzulu zaseMelika zipapashe inqaku lengxoxo kwi-J DRUGS DERMATOL malunga nokongeza i-NAD precursors NMN kunye ne-NR ukunciphisa umngcipheko womhlaza we-keratinocyte.
Umbhali ucinga ukuba i-nicotinamide (NAM), njengesandulela se-NAD+, ingqinwe nguChoy B kunye nezinye izazinzulu ukuba iyanciphisa ukwanda komhlaza we-keratinocyte. Nangona kunjalo, i-nicotinamide mononucleotide (NMN) kunye ne-nicotinamide nucleoside (NR), ezikwangandulela ukwenziwa kwe-NAD+, zinokuba sisongezelelo esisebenzayo ekunciphiseni ukwanda komhlaza we-keratinocyte.
Ukunikezelwa ngomlomo kwe-NMN kunye ne-NR kunokunyusa ngempumelelo inqanaba le-NAD+
Ngo-2018, uSinclair DA kunye nezinye izazinzulu babonakalise ukuba xa kuthelekiswa ne-NAM, ukuthatha i-NMN kunye ne-NR ngomlomo ukunyanga abantu kunye neempuku kunyusa inqanaba le-NAD+ egazini nasesibindini, ngokwahlukeneyo. Ngenxa yoko, i-NMN kunye ne-NR zenze i-NAD+ ngempumelelo ngakumbi.
I-NMN kunye ne-NR zikhuselekile kwaye zinyamezeleka ngcono
Izongezo ze-NMN kunye ne-NR zisetyenziswa kakhulu ebantwini nakwizilwanyana, kwaye akukho tyhefu okanye iziphumo ebezingalindelekanga ezibikiweyo ukuza kuthi ga ngoku. Uphononongo lweklinikhi kubafazi abangama-25 abangaphambi kokuya exesheni abanesifo seswekile bathathe izongezo ze-NMN ngomlomo ngedosi ye-250 mg/ngosuku, kwaye bafumanise ukuba i-NMN yonyusa uvakalelo lwe-insulin yemisipha ngaphandle kokubangela naziphi na iziganeko ezimbi. Uphononongo lwesibini lweklinikhi lugxile kwisiphumo sokongeza i-NMN kumandla e-aerobic abagijimi. Abathathi-nxaxheba abangama-36 bafumana i-300 mg/ngosuku (n=12), i-600 mg/ngosuku (n=12) okanye i-1200 mg/ngosuku (n=12) NMN, kwaye akukho ziphumo bezingalindelekanga okanye iziganeko ezimbi ezibikiweyo. Nangona i-US Food and Drug Administration (FDA) ingekavumi ezi zithako zimbini zezongezo zokutya, izongezo ze-NMN kunye ne-NR zinokuthengwa ngokulula kwi-intanethi, kwaye abathengi abaninzi baqalile ukuzithatha, ngeedosi eziqala kwi-500mg ukuya kwi-1000mg/ngosuku. Akukho ziganeko zimbi zifunyenweyo.
Xa kuthelekiswa ne-NAM, i-NMN yomlomo kunye ne-NR inokunyusa izinga le-NAD+ ngokufanelekileyo kwaye ibe nokhuseleko olungcono kunye nokunyamezelana okungcono, eli licebo lonyango olunokwenzeka kwiingcali zesikhumba ukunciphisa umngcipheko womhlaza we-keratinocyte. Nangona kunjalo, isadinga idatha eninzi yophando lweklinikhi ukuqinisekisa ukusetyenziswa kwayo okusebenzayo kunyango lweklinikhi.
Iireferensi:
[1]. Kahn B, Borrelli M, Libby T. Uphononongo lweNdaba lweNicotinamide Adenine Dinucleotide (NAD)+ Intermediates Nicotinamide Riboside kunye neNicotinamide Mononucleotide yokunciphisa umngcipheko weKeratinocyte Carcinoma. J Drugs Dermatol. 2022 Oct 1;21(10):1129-1132. doi: 10.36849/JDD.6870. PMID: 36219044.
Ixesha lokuthumela: Okthobha-25-2022